^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Excerpt:
...- HR+ HER2- breast cancer harboring an FGFR2 gene amplification....
Trial ID:
Source:
Title:
A study to evaluate the effects of TAS-120 in patients with Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
Excerpt:
...HR+ HER2- breast cancer harboring an FGFR2 gene amplification. ...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
Published date:
11/18/2023
Excerpt:
Nine breast cancer patient-derived xenografts (PDXs) with various FGFR1-4 alterations and expression levels were treated with futibatinib....Futibatinib inhibited tumor growth in 3 of 9 PDXs, with tumor stabilization in an FGFR2-amplified model and prolonged regression (> 110 days) in an FGFR2 Y375C mutant/amplified model. FGFR2 overexpression and, to a greater extent, FGFR2 Y375C expression in MCF10A cells enhanced cell growth and sensitivity to futibatinib....More limited antitumor effects were seen in BCX.080, which had high RNA expression of FGFR3 and FGFR4.
DOI:
10.1038/s41598-023-46586-y
Source:
Title:
Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Published date:
09/22/2021
Excerpt:
Among the 170 patients who received futibatinib 20 mg QD, 10.6% experienced PRs, and 38.2% experienced SD...In addition, patients with tumors harboring FGFR2 amplifications (gastric and breast cancer)...also had targetlesion shrinkage...futibatinib led to an objective response in 1 patient with gastric cancer and 1 patient with breast cancer harboring FGFR2 amplifications.
DOI:
10.1158/2159-8290.CD-21-0697
Trial ID:
Source:
Title:
544P - Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours
Published date:
09/14/2020
Excerpt:
FBN showed manageable safety and preliminary efficacy in Japanese pts with adv solid tumors...partial responses were observed in pts with gastric (n=2; tumor shrinkages of 59% and 70%) and breast cancer (n=1; tumor shrinkage, 37%) harboring FGFR2 amplifications.
Source:
Title:
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Published date:
11/01/2020
Excerpt:
Across all tumor types studied, futibatinib inhibited the growth of cell lines with various FGFR genomic aberrations, but not of cell lines that did not harbor such aberrations....These FGFR aberrations included FGFR1/2 amplifications (breast cancer), FGFR1 amplifications (lung cancer), FGFR2 amplifications (gastric cancer), FGFR2 point mutations (endometrial cancer), FGFR3 fusions (bladder cancer), and FGFR3 translocations (multiple myeloma; Table 1...).
DOI:
10.1158/0008-5472.CAN-19-2568
